Search
Alphacetylmethadol
go.drugbank.com/drugs/DB01555ExperimentalIllicitIt is used mainly in the treatment of narcotic dependence. [PubChem]
Nicotinyl alcohol
go.drugbank.com/drugs/DB04145ExperimentalIt is used in vasospasm and threatened gangrene. [PubChem]
Pradofloxacin
go.drugbank.com/drugs/DB11453ExperimentalVet approvedIt was approved by the European Commission in April 2011 for bacterial infections in dogs and cats. … Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH.
Phthalocyanine
go.drugbank.com/drugs/DB12983InvestigationalI or Stage II Mycosis Fungoides). … Phthalocyanine is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage
Atigotatug
go.drugbank.com/drugs/DB14831InvestigationalBMS-986012 is a human antifucosyl-GM1 antibody. It is under investigation in clinical trial NCT02815592 (Trial of BMS-986012 in Combination With Platinum and Etoposide).
Leukotriene C4
go.drugbank.com/drugs/DB08855ExperimentalIt is the major arachidonic acid metabolite in macrophages and human mast cells as well as in antigen-sensitized lung tissue. … It stimulates mucus secretion in the lung, and produces contractions of nonvascular and some vascular smooth muscle. (From Dictionary of Prostaglandins and Related Compounds, 1990)
Talarozole
go.drugbank.com/drugs/DB13083InvestigationalTalarozole has been investigated for the treatment of Psoriasis and Cutaneous Inflammation.
Nalorphine
go.drugbank.com/drugs/DB11490ExperimentalVet approvedIt acts at two opioid receptors—at the mu receptor it has antagonistic effects, and at the kappa receptors it exerts high-efficacy agonistic characteristics. … It is used to reverse opioid overdose and (starting in the 1950s) in a challenge test to determine opioid dependence.
Favezelimab
go.drugbank.com/drugs/DB16729InvestigationalFavezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A